SCHEMBL308031

SCHEMBL308031

Cc1cc(-c2ccccc2)ccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 2/20 0.52
CYP1A2 P05177 1/20 0.48
AHR P35869 1/20 0.44
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
ERCC5 P28715 1/20 0.42
FEN1 P39748 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42
ALOX5 P09917 1/20 0.41
ALDH1A1 P00352 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
BRD4 O60885 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
PTGS2 P35354 2/20 0.40
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL11017797 0.98 ESR2 (0.50) ESR2CYP1A2AHRHSD17B1HSD17B2
SCHEMBL4300888 0.88 AHR (0.55) ESR2AHRALDH1A1TDP1MEN1
Ether SCHEMBL11017793 0.87 RAB9A (0.43) ESR2CYP1A2ERCC5FEN1KDM4E
SCHEMBL16168616 0.84 AHR (0.46) ESR2AHRALDH1A1TDP1L3MBTL1
SCHEMBL23627967 0.82 L3MBTL1 (0.53) CYP1A2ALDH1A1TDP1L3MBTL1KDM4E
SCHEMBL31614097 0.82 ESR2 (0.57) ESR2CYP1A2AHRTNKS2ALOX5
SCHEMBL1755256 0.82 ESR2 (0.57) ESR2CYP1A2AHRTNKS2ALOX5
SCHEMBL28210399 0.80 ESR2 (0.53) ESR2AHRHSD17B1HSD17B2ALOX5
SCHEMBL18970409 0.79 TAAR1 (0.50) ESR2TNKS2MAPTHPGDPTGS2
SCHEMBL621796 0.78 ESR2 (0.53) ESR2CYP1A2AHRHSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093245-B2 Anticancer agents; potent Deoxycytidine kinase inhibitors; inhibit thymidine kinase; inhibit uridine kinase; N-[3-(4-amino-5-fluoro-2-oxo-2H-pyrimidin-1-yl)-cyclopentyl]-3-bromo-benzenesulfonamide LEXICON PHARMACEUTICALS, INC. (US) 2012-01-10 US disclosed
US-20080182847-A1 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE OXFORD FINANCE LLC, AS COLLATERAL AGENT 2008-07-31 US disclosed
US-20040167193-A1 Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-26 US disclosed
US-6762197-B2 FUNGICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-07-13 US disclosed
US-20030119670-A1 Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-06-26 US disclosed
EP-1238975-A1 DIFLUOROMETHYLTRIAZOLONE COMPOUNDS, USE OF THE SAME AND INTERMEDIATES FOR THE PRODUCTION THEREOF Sumitomo Chemical Company, Limited (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167193-A1 Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof CYP51A1, DPM1, CYP1A1 ESR2 3163/4885CYP1A2 40/4885AHR 134/4885
US-20080182847-A1 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE TPMT, DHFR, GLS2 ESR2 366/4885CYP1A2 301/4885AHR 379/4885
US-20030119670-A1 Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof CYP51A1, DPM1, CYP1A1 ESR2 3163/4885CYP1A2 40/4885AHR 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.